This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ACGN Aperçu des actions
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
+ 2 plus de risques
Aceragen, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.38 |
| Plus haut sur 52 semaines | US$16.00 |
| Plus bas sur 52 semaines | US$0.36 |
| Bêta | 1.14 |
| 1Variation sur 1 mois | -48.99% |
| Variation sur 3 mois | -76.54% |
| Variation sur 1 an | -95.55% |
| 3Variation sur 3 ans | -98.96% |
| Variation sur 5 ans | -99.78% |
| Évolution depuis l'introduction en bourse | -100.00% |
Nouvelles et mises à jour récentes
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Rendement pour les actionnaires
| ACGN | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -11.6% | 6.1% | 4.2% |
| 1Y | -95.5% | 20.1% | 24.4% |
Rendement vs Industrie: ACGN underperformed the US Biotechs industry which returned 6.3% over the past year.
Rendement vs marché: ACGN underperformed the US Market which returned 4.2% over the past year.
Volatilité des prix
| ACGN volatility | |
|---|---|
| ACGN Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: ACGN's share price has been volatile over the past 3 months.
Volatilité au fil du temps: ACGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Aceragen, Inc. Résumé des fondamentaux
| ACGN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$3.20m |
| Bénéfices(TTM) | -US$41.05m |
| Recettes(TTM) | US$7.33m |
0.4x
Ratio P/S-0.1x
Ratio P/ELe site ACGN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ACGN compte de résultat (TTM) | |
|---|---|
| Recettes | US$7.33m |
| Coût des recettes | US$15.40m |
| Marge brute | -US$8.06m |
| Autres dépenses | US$32.98m |
| Les revenus | -US$41.05m |
Derniers bénéfices déclarés
Mar 31, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -4.88 |
| Marge brute | -110.00% |
| Marge bénéficiaire nette | -559.86% |
| Ratio dettes/capitaux propres | 1.3% |
Quelles ont été les performances à long terme de ACGN?
Voir les performances historiques et les comparaisons